1 / 26

Inherited Renal Diseases Part II

Inherited Renal Diseases Part II. Maria Ferris and Deb Gipson 10/23/01. Outline. Lowe Syndrome Fabry disease Cystinosis Cystinuria Hyperoxaluria Alports. Fabry Disease. X-linked recessive disorder (Xq22-24) Defect is in the alpha-1 galactosidase A

ashlyn
Télécharger la présentation

Inherited Renal Diseases Part II

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Inherited Renal DiseasesPart II Maria Ferris and Deb Gipson 10/23/01

  2. Outline • Lowe Syndrome • Fabry disease • Cystinosis • Cystinuria • Hyperoxaluria • Alports

  3. Fabry Disease • X-linked recessive disorder (Xq22-24) • Defect is in the alpha-1 galactosidase A • Diagnosis by assay of peripheral blood leukocyte level of alpha-galactosidase • Hemizygous(M) level is near 0 • Heterozygote (F) level may be in the low normal range. Check urinary ceramide digalactoside and trihexoside. • Fetus: determine level in amniocyte

  4. Fabry Disease • Males: wide range of clinical abnormalities • Females: variable range of clinical expression, may have lipid storage in cells and be completely asymptomatic (lyonization) • Race: White most common • Incidence: 1:40,000 • Intracellular accumulation of the glycosphingolipid galabiosylceramide

  5. Fabry: Deposition • *Endothelial, perithelial, smooth muscle of blood vessels • Kidney: glomerluar and tubular epithelium • Corneal epithelium • Myocardium • Autonomic NS: ganglion cells • RES: bone marrow, liver, spleen, lymph nodes • Lungs, synovial lining and testes

  6. Fabry: Clinical Manifestations • angiokeratoma (age 10-20) appearance dark red macules or papules • acroparesthesias exacerbated by fever and exercise (childhood) • anhidrosis (tears and saliva) • Nausea, abdominal pain, diarrhea • ophthalmic abnormalities: corneal opacity, posterior cataracts, • ischemic cerebrovascular disease: seizure, TIA, stroke • ischemic heart disease: MI, dysrhythmias

  7. Angiokeratoma

  8. Kidney • mild proteinuria (0.5-2g/d) in the 3rd decade • Uremia and hypertension in the 4-5th decade • ESRD as early as 2nd decade • Urine: myelin bodies, mild hematuria

  9. Pathology • Uniform-size empty vacuoles (formalin) • Most striking in visceral epithelial cells of glomeruli • Less in renal arterioles, tubular epithelium, mesangium, interstitium • Birefringence and Maltese-cross w/ polarized optics (fresh or frozen) • Progressive disease: segmental and global glomerulosclerosis

  10. Pathology • IF is negative • EM: cellular inclusions in all glomerular cells • Zebra bodies or myelin figures • Onion skin appearance • Located in lysosomes • Foot process effusion w/ heavy proteinuria • DDX: • Pulmonary Scilicosis W/ hematuria and proteinuria: inclusions in glomeruli • Clororquine therapy: inclusions in glomeruli • Aminoglycoside: inclusions in tubules

  11. M&M in Fabry Disease • Natural Hx: death at mean age of 42 from uremia • Treated for ESRD: most common causes of death are cerebrovascular and cardiovascular • After transplant, the glycosphingolipid deposits recur but do not limit renal function • New Rx: IV alpha-galactosidase q 2 weeks. Approved in Europe last month. Awaiting FDA approval in US

  12. Alport Syndrome • Inheritance • Classic X-linked dominant • AR • AD • Gene: COL4A5 encodes for the alpha 5 chain of type IV collagen • Gene frequency 1:10,000

  13. Alport Clinical Features • Hematuria: microscopic may be persistent, gross hematuria is intermittent if present. Onset 0-10 yrs • Proteinuria: absent in the first few years of life and then becomes gradually progressive. • Hypertension-progressive • Renal survival • Males: nearly all affected progress to ESRD; Age is variable • Females: better prognosis (X-linked variety); presence of gross hematuria in childhood, nephrotic syndrome, and diffuse GBM thickening are poor prognostic signs

  14. Alport Syndrome • Sensorineural hearing loss: onset by age 15 in males. Detect by audiometry. Progressive. In females progressive hearing loss is a poor prognostic sign • Ocular defects: 15-30% • Anterior lenticonus • Corneal endothelial vesicles • Platelet defects: megathrombocytopenia + platelet dysfunction (AD) • Diffuse leiomyomatosis: upper GI tract, tracheobronchial tree, females genital. Posterior subcapsular cataracts. (AD)

  15. Alport Nephropathology: Light • < 5 years: nearly nl w/ occasional interstitial foam cells and fetal glomeruli • mesangial widening • focal thickening of Bowman’s capsule • focal endothelial and mesangial proliferation • split capillary walls • progressive glomerular sclerosis • TBM thickening • interstitial fibrosis and foam cells; tubular atrophy • occasional crescents • capsular tuft synechiae

  16. Nephropathology • IF • Typically negative • Increased deposition w/ sclerosis • EM * Variable thickening, thinning, basket weaving, and lamellation of the GBM

  17. Alport Syndrome

  18. Alport: Prognosis • Post transplant • 5% Anti-GBM nephritis • responds to therapy • likely to recur in next allograft • Hearing deficit • may progress to total deafness • Treatment • supportive

  19. Primary Hereditary Hyperoxaluria • Type I • hyperoxaluria w/ glycolic aciduria • alanine: glyoxylate aminotransferase deficiency (peroxisome) • autosomal recessive; 1:60,000-120,000 • Type II • hyperoxaluria w/ L-glyceric aciduria • D-glycerate dehydrogenase deficiency (cytosol) • very rare • Type III • Intestinal hyperoxaluria (hyperabsorptive)

  20. (1)glycine cleavage enzyme; (2) alanine: glyoxylate aminotransferase; (3) D-glyceric acid dehydrogenase; (4) glycerate kinase; (5) trimethylamine oxidase; (6) lactate dehydrogenase; (7) glycolate oxidase; (8) NKH* = nonketotic hyperglycinemia; TH4 =tetrahydrofolate. Behrman: Nelson Textbook of Pediatrics, 16th ed. 2000

  21. Metabolic PathwayDefective in PH-I glyoxalate Pyridoxine Alanine:glyoxylate aminotransferase (liver) oxalate glycine

  22. Primary Hyperoxaluria-I: Laboratory • Elevated urinary sodium, oxalate, glycolic acid, and glyoxylic acid • Laboratory Normal Values • Blood oxalate 10-140 mg/dl • Urine oxalate 10-40 mg/day • Oxalate/Creatinine urine • Infants < 0.3 mg/mg • 1-5 yo < 0.1 mg/mg • >5 yo < 0.05 mg/mg

  23. Pathology • Hyperoxalemia: wide spread deposition of oxalate = oxalosis • Renal deposition: nephrolithiasis, tubulointerstitial nephropathy, renal failure • Light Microscopy: calcium oxalate crystalline deposits in tubule, interstitium, interstitial fibrosis, late focal glomerular sclerosis. Stone in calyceal system are birefringent

  24. blood vessel walls bone bone marrow (myelopthesis) joints heart spleen liver thymus pituitary adrenal pancreas parathyroids thyroid brain heart (conduction defects) Extrarenal deposition

  25. Primary Hyperoxaluria

  26. Primary Hyperoxaluria - ITreatment • Early diagnosis • Dietary restriction of glycine and high oxalate foods (spinach, rhubarb, beet roots, iced tea) • Pyridoxine • Hydration to limit stone formation (2.5 L/m2) • + Mg and phosphate supplementation • Liver / Kidney transplant

More Related